Three Decades of Amyloid Beta Synthesis: Challenges and Advances

Aggregation of the pathological amyloid beta (Aβ) isoform Aβ(1−42) into senile plaques is a neuropathological hallmark of Alzheimer's disease (AD). The biochemical significance of this phenomenon therefore necessitates the need for ready access to Aβ(1−42) for research purposes. Chemical synthesis of the peptide, however, is technically difficult to perform given its propensity to aggregate both on resin during solid phase peptide synthesis and in solution during characterization. This review presents a chronological summary of key publications in the field of Aβ(1−42) synthesis, dating back from its maiden synthesis by Burdick et al. Challenges associated with the preparation of Aβ(1−42) were identified, and the solutions designed over the course of time critically discussed herein. Ultimately, the intention of this review is to provide readers with an insight into the progress that has been made in the last three decades, and how this has advanced broader research in AD.